Pyrazinamide (PZA) is a medication used to treat tuberculosis. Moreover, for active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. Pyrazinamide kills non-replicating persister cells that other medication of TB fail to kill, and for which it became important drug for inclusion in any drug combinations for treating drug susceptible and drug-resistant TB such as MDR-TB. It acts variably compared to other antibiotics by inhibiting energy production, trans-translation, and co-enzyme A required for persister survival. The increasing mutation in drug targeted gene is marking bacterial strain more resistant to PZA drug. The recently panD mutations gene was found along with pncA or rpsA mutations gene in bacterial resistant strains.
Market Dynamics
The high burden of TB is expected to drive growth of the market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa, which accounted for two thirds of the new TB cases.
The increasing global burden of TB is expected to drive the pyrazinamide market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to the WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$ 12 billion in additional economic costs and lost productivity. Thus, increasing healthcare spending on treatment of TB is expected to drive growth of the market.
Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in R&D activities for development of novel therapies for treatment of TB is expected to restrain growth of the pyrazinamide drugs market. For instance, according to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017, with an increase of 6% (or US$ 46 million), compared to US$ 726 million in 2016.
Key features of the study
• This report provides in-depth analysis of the global pyrazinamide market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
• It profiles key players in the global pyrazinamide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global pyrazinamide market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts
Market Segmentation
• By Patient Type (Revenue, USD Bn, 2021-2033)
o Adult
o Pediatric
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Pyrazinamide Market, By Region (Revenue, USD Bn, 2021-2033)
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Europe
 Germany
 U.K.
 France
 Italy
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East
 GCC
 Israel
 Rest of Middle East
o Africa
 South Africa
 Central Africa
 North Africa
• Key Players
o Pure Chemistry Scientific
o LGM Pharma
o TCI
o HBCChem
o Alfa Chemistry
o Toronto Research Chemicals
o Acros Organics
o AlliChem
o Waterstone Technology
o City Chemical
o EDQM
o J & K SCIENTIFIC
o Meryer (Shanghai) Chemical Technology
o Energy Chemical
o Beijing Ouhe Technology

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
 Market Definition and Scope
o Executive Summary
 Global Pyrazinamide Market, By Patient Type
 Global Pyrazinamide Market, By Distribution Channel
 Global Pyrazinamide Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trend
4. Global Pyrazinamide Market, By Patient Type, 2021-2033, (USD Bn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Adult
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Pediatric
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Pyrazinamide Market, By Distribution Channel, 2021-2033, (USD Bn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Hospital Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Retail Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Online Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Pyrazinamide Market, By Region, 2021 - 2033, Value (USD Bn)
o Introduction
 Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)
 Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
 Regional Trends
o North America
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o U.S.
o Canada
o Latin America
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
 Introduction
 Market Size and Forecast, By Patient Type, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o South Africa
o North Africa
o Central Africa
7. Competitive Landscape
o Pure Chemistry Scientific
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o LGM Pharma
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o TCI
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o HBCChem
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Alfa Chemistry
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Toronto Research Chemicals
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Acros Organics
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o AlliChem
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Waterstone Technology
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o City Chemical
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o EDQM
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o J & K SCIENTIFIC
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Meryer (Shanghai) Chemical Technology
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Energy Chemical
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Beijing Ouhe Technology
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
8. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
9. References and Research Methodology
o References
o Research Methodology
o About us